Tag: SABCS

SABCS 2025: Combination of Invikafusp Alfa and Sacituzumab Govitecan Demonstrates Positive Results in Ongoing Study

The current study results presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) confirm the encouraging efficacy seen in previously treated patients with metastatic and locally advanced breast cancer subtypes, particularly in earlier lines of therapy. The safety and tolerability of Izalontamab Brengitecan are consistent with previously published data.

Updated safety & efficacy data from a phase 1 clinical study evaluating BL-B01D1 (SystImmune; see Drugmap), a bispecific topoisomerase inhibitor-based antibody-drug conjugates that targets both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) in locally advanced or metastatic breast cancer patients will be presented in a poster at the San Antonio Breast Cancer Symposium (SABCS) 2024, taking place on December 10-13 in San Antonio, Texas.

Zelenectide pevedotin, comprised of a bicyclic peptide targeting Nectin-4 conjugated via a valine-citrulline cleavable linker to monomethyl auristatin E (MMAE), has demonstrated enhanced anti-tumor activity in triple-negative breast cancer (TNBC-) patients with Nectin-4 gene amplification.

Updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin (SGN-LIV1A) in patients with metastatic triple negative breast cancer (mTNBC), was presented...

Data covering the completed dose escalation portion of its Phase I study of ZW25 (Zymeworks) , a novel Azymetric™ bispecific antibody targeting two distinct...

Data from an ongoing phase I clinical trial evaluating SGN-LIV1A for patients with metastatic breast cancer (MBC), with particular focus on metastatic triple-negative breast...

Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in December...

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast cancer who had received...

Positive preclinical data for Mersana Therapeutics'  lead product candidate, XMT-1522, demonstrates significant anti-cancer activity in both HER2-positive and HER2 low-expressing tumor models refractory to...